$0.55 EPS Expected for Saratoga Investment Corp. (SAR); Lincluden Management LTD Has Decreased Pfizer (PFE) Holding



Analysts expect Saratoga Investment Corp. (NYSE:SAR) to report $0.55 EPS on January, 9.They anticipate $0.01 EPS change or 1.85% from last quarter’s $0.54 EPS. SAR’s profit would be $4.11M giving it 10.02 P/E if the $0.55 EPS is correct. After having $0.69 EPS previously, Saratoga Investment Corp.’s analysts see -20.29% EPS growth. The stock decreased 0.18% or $0.04 during the last trading session, reaching $22.04. About 46,316 shares traded or 25.83% up from the average. Saratoga Investment Corp. (NYSE:SAR) has risen 1.68% since December 16, 2017 and is uptrending. It has outperformed by 1.68% the S&P500. Some Historical SAR News: 18/05/2018 – Sandestin Investments Taps Highgate to Manage New Hotel; 14/05/2018 – Saratoga Investment 4Q EPS 89c; 30/05/2018 – Saratoga Investment Corp. Increases Quarterly Dividend To $0.51 Per Share; 07/03/2018 – Saratoga Hospital partners with Philips to improve patient care and safety; 07/03/2018 SARATOGA HOSPITAL PARTNERS W/ PHILIPS; 08/03/2018 – Saratoga Springs Plastic Surgeon Named 2018 “Top Doctor” in Albany, NY Metro Area; 07/03/2018 – KONINKLIJKE PHILIPS NV PHG.AS ANNOUNCES INTEGRATION OF PHILIPS INTELLIVUE GUARDIAN INTO GENERAL CARE UNITS OF SARATOGA HOSPITAL; 08/03/2018 – Saratoga Springs Plastic Surgeon Named 2018 “Top Doctor” in Albany, NY Metro Area; 14/05/2018 – SARATOGA INVESTMENT CORP – FOR QTR ENDED FEB 28, AUM WAS $342.7 MLN VS $338.8 MLN FOR QTR ENDED NOVEMBER 30, 2017; 11/04/2018 – Interior-Parks: National Park Week at Saratoga
Lincluden Management Ltd decreased Pfizer Inc (PFE) stake by 11.34% reported in 2018Q3 SEC filing. Lincluden Management Ltd sold 23,565 shares as Pfizer Inc (PFE)’s stock rose 5.56%. The Lincluden Management Ltd holds 184,213 shares with $8.12M value, down from 207,778 last quarter. Pfizer Inc now has $253.19 billion valuation. The stock decreased 1.73% or $0.77 during the last trading session, reaching $43.8. About 31.33M shares traded or 36.32% up from the average. Pfizer Inc. (NYSE:PFE) has risen 25.07% since December 16, 2017 and is uptrending. It has outperformed by 25.07% the S&P500. Some Historical PFE News: 24/05/2018 – Pfizer under pressure to resolve shortage of life-saving EpiPen; 07/05/2018 – PFIZER INDIA QTR REVENUE 5.2B RUPEES; 08/03/2018 – MERCK MRCG.DE CEO SAYS PARTNERSHIP WITH PFIZER PFE.N IS VERY SOLID; 09/05/2018 – PFIZER SAYS EPIPEN PRODUCT REMAINS AVAILABLE; 01/05/2018 – Pfizer 1Q Innovative Health Rev $7.83B; 21/03/2018 – RECKITT BENCKISER SAYS ENDED TALKS W/ PFIZER ON CONSUMER HEALTH; 13/04/2018 – STAT Plus: Pharmalittle: Sanofi warns Canada over industry treatment; Pfizer got a big boost from the new tax law; 25/05/2018 – IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non; 03/04/2018 – Pfizer in talks with P&G for consumer health unit sale – CNBC; 18/05/2018 – U.S. FDA SAYS THERE WAS NO CHANGE IN THE ADVERSE EVENT PROFILE OF KEYTRUDA OR TECENTRIQ
Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on January, 29. They expect $0.64 earnings per share, up 3.23% or $0.02 from last year’s $0.62 per share. PFE’s profit will be $3.70B for 17.11 P/E if the $0.64 EPS becomes a reality. After $0.78 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -17.95% negative EPS growth.
Investors sentiment increased to 0.85 in 2018 Q3. Its up 0.07, from 0.78 in 2018Q2. It improved, as 41 investors sold PFE shares while 741 reduced holdings. 142 funds opened positions while 520 raised stakes. 3.96 billion shares or 0.44% less from 3.98 billion shares in 2018Q2 were reported. First Quadrant LP Ca has invested 0.94% in Pfizer Inc. (NYSE:PFE). Contravisory Inv Mngmt Incorporated has invested 0.01% in Pfizer Inc. (NYSE:PFE). Violich Cap Mngmt accumulated 26,470 shares or 0.27% of the stock. Wellington Shields And Ltd Liability reported 55,468 shares or 1.32% of all its holdings. Santa Barbara Asset Mgmt Ltd Llc holds 4.36 million shares. Gemmer Asset Ltd Liability Co, a California-based fund reported 28,515 shares. Thrivent Fincl For Lutherans has invested 0.54% in Pfizer Inc. (NYSE:PFE). Gulf Comml Bank (Uk) Ltd has 1.04% invested in Pfizer Inc. (NYSE:PFE). Neumann Cap Llc has invested 0.15% in Pfizer Inc. (NYSE:PFE). Cooke & Bieler Limited Partnership invested in 0% or 5,600 shares. Bollard Group Incorporated Limited Liability Co accumulated 80,936 shares. 9,747 were reported by Ipg Inv Advsr Lc. Ontario – Canada-based Ontario Teachers Pension Plan Board has invested 0.28% in Pfizer Inc. (NYSE:PFE). Pinnacle Wealth Advisory Gru Ltd Limited Liability Company owns 0.83% invested in Pfizer Inc. (NYSE:PFE) for 38,048 shares. Hexavest Incorporated reported 3.09% of its portfolio in Pfizer Inc. (NYSE:PFE).
More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “Pfizer Receives FDA Approval For AML Drug – Seeking Alpha” on November 27, 2018, also Streetinsider.com with their article: “Pfizer (PFE) Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV – StreetInsider.com” published on December 14, 2018, Seekingalpha.com published: “Pfizer among those seen hiking payouts next week – Seeking Alpha” on December 14, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer Inc. (PFE) Management Presents on Evercore ISI HealthCONx Conference Call Transcript – Seeking Alpha” published on November 28, 2018 as well as Fool.com‘s news article titled: “Where Will Pfizer Inc. Be in 5 Years? – The Motley Fool” with publication date: November 17, 2018.
Among 7 analysts covering Pfizer (NYSE:PFE), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Pfizer had 9 analyst reports since August 1, 2018 according to SRatingsIntel. Credit Suisse maintained Pfizer Inc. (NYSE:PFE) on Wednesday, August 1 with “Neutral” rating. The firm has “Overweight” rating by Morgan Stanley given on Thursday, August 23. Credit Suisse maintained the stock with “Neutral” rating in Wednesday, October 31 report. The company was maintained on Wednesday, August 1 by Bank of America. The rating was maintained by Citigroup on Tuesday, November 6 with “Sell”. Barclays Capital maintained the stock with “Equal-Weight” rating in Thursday, August 23 report. As per Thursday, November 1, the company rating was downgraded by BMO Capital Markets. BMO Capital Markets maintained the stock with “Outperform” rating in Wednesday, August 1 report. On Tuesday, December 11 the stock rating was downgraded by JP Morgan to “Neutral”.
Since July 20, 2018, it had 0 buys, and 2 insider sales for $1.92 million activity. On Friday, July 20 the insider SUSMAN SALLY sold $1.50M. OLSON LAURIE J sold $418,774 worth of stock or 10,214 shares.
Among 2 analysts covering Saratoga Investment (NYSE:SAR), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Saratoga Investment had 2 analyst reports since July 16, 2018 according to SRatingsIntel. The firm has “Neutral” rating by Ladenburg Thalmann given on Monday, July 16. As per Monday, July 16, the company rating was upgraded by Compass Point.
More notable recent Saratoga Investment Corp. (NYSE:SAR) news were published by: Seekingalpha.com which released: “Saratoga Investment declares $0.53 dividend – Seeking Alpha” on November 27, 2018, also Globenewswire.com with their article: “New Research Coverage Highlights Beasley Broadcast Group, Resolute Energy, Hanger, Inspired Entertainment, Saratoga Investment, and iRadimed — Consolidated Revenues, Company Growth, and Expectations for 2018 – GlobeNewswire” published on November 16, 2018, Seekingalpha.com published: “Saratoga Investment Corp.: This 6.25% Baby Bond Has Begun Trading On The NYSE – Seeking Alpha” on August 31, 2018. More interesting news about Saratoga Investment Corp. (NYSE:SAR) were released by: Seekingalpha.com and their article: “Saratoga Investment Corp.: 8.2% Yield, Solid Growth Prospects, High Dividend Coverage – Seeking Alpha” published on July 15, 2018 as well as Seekingalpha.com‘s news article titled: “A Safe 9% Yielder With 16 Straight Dividend Increases And Interest Rate Protection – Seeking Alpha” with publication date: October 17, 2018.
Saratoga Investment Corp. is a business development firm specializing in leveraged and management buyouts, acquisition financings, growth financings, recapitalization, debt refinancing, and transitional financing transactions at the lower end of middle market companies. The company has market cap of $164.86 million. It structures its investments as debt and equity by investing through first and second lien loans, mezzanine debt, co-investments, select high yield bonds, senior secured bonds, unsecured bonds, and preferred and common equity. It has a 8.36 P/E ratio. It seeks to invest in the United States.

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more